Fmr LLC increased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 9.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,824,306 shares of the medical device company’s stock after purchasing an additional 978,898 shares during the period. Fmr LLC owned approximately 12.50% of DexCom worth $791,799,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Capstone Asset Management Co. purchased a new stake in DexCom in the 1st quarter valued at about $213,000. Great West Life Assurance Co. Can boosted its position in DexCom by 6.4% in the 1st quarter. Great West Life Assurance Co. Can now owns 27,413 shares of the medical device company’s stock valued at $2,320,000 after buying an additional 1,647 shares during the period. BNP Paribas Arbitrage SA boosted its position in DexCom by 238.8% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,476 shares of the medical device company’s stock valued at $379,000 after buying an additional 3,155 shares during the period. World Asset Management Inc purchased a new stake in DexCom in the 1st quarter valued at about $317,000. Finally, UBS Asset Management Americas Inc. boosted its position in DexCom by 14.1% in the 1st quarter. UBS Asset Management Americas Inc. now owns 248,178 shares of the medical device company’s stock valued at $21,028,000 after buying an additional 30,737 shares during the period.

Several equities research analysts have issued reports on DXCM shares. Oppenheimer Holdings, Inc. set a $92.00 price objective on shares of DexCom and gave the company a “buy” rating in a research report on Wednesday, August 2nd. Cowen and Company reissued a “buy” rating and issued a $90.00 price objective on shares of DexCom in a research report on Friday, July 14th. BMO Capital Markets reissued a “buy” rating and issued a $105.00 price objective on shares of DexCom in a research report on Thursday, July 13th. Piper Jaffray Companies reissued a “buy” rating and issued a $78.00 price objective on shares of DexCom in a research report on Wednesday, July 12th. Finally, BidaskClub raised shares of DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, June 21st. Seven research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $86.87.

DexCom, Inc. (NASDAQ:DXCM) opened at 69.99 on Friday. The company’s 50 day moving average is $72.62 and its 200 day moving average is $73.86. DexCom, Inc. has a 1-year low of $57.68 and a 1-year high of $94.79. The company’s market cap is $6.06 billion.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.07. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The company had revenue of $170.60 million during the quarter, compared to the consensus estimate of $166.54 million. During the same quarter in the previous year, the firm earned ($0.24) earnings per share. The firm’s quarterly revenue was up 24.3% on a year-over-year basis. Equities research analysts forecast that DexCom, Inc. will post ($0.78) EPS for the current year.

In related news, EVP Andrew K. Balo sold 3,200 shares of DexCom stock in a transaction that occurred on Monday, July 10th. The shares were sold at an average price of $71.55, for a total value of $228,960.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin R. Sayer sold 6,000 shares of DexCom stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $69.34, for a total transaction of $416,040.00. The disclosure for this sale can be found here. Insiders sold 30,773 shares of company stock valued at $2,183,913 in the last quarter. 1.70% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: “DexCom, Inc. (DXCM) Position Boosted by Fmr LLC” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/24/dexcom-inc-dxcm-position-boosted-by-fmr-llc.html.

DexCom Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.